All News
Filter News
Found 760 articles
-
Mirimus, Inc. Forms Strategic Collaboration with Biogen to Develop RNAi-Based Therapeutics for Neurological Disease Indications
7/21/2021
Mirimus, Inc. today announced a strategic collaboration with Biogen Inc. (NASDAQ: BIIB) focused on the development of RNAi-based therapeutics targeting multiple, undisclosed neurological disease indications.
-
Frontier Medicines will support the continued development of the company’s chemoproteomics drug discovery program, including lead asset, an inhibitor of KRASG12C.
-
Frontier Medicines Raises $88.5 Million Series B Financing to Advance Precision Oncology and Targeted Protein Degradation Pipeline
7/19/2021
Frontier Medicines Corporation, a precision medicine company seeking to unlock the proteome to advance breakthroughs against otherwise undruggable disease-causing targets, announced the closing of an $88.5 million Series B financing round.
-
Advaxis Announces Initiation of Phase 1 Clinical Trial of ADXS-504 for the Treatment of Early Prostate CancerStudy in biochemically recurrent prostate cancer expands off-the-shelf ADXS-HOT program to second indication
7/15/2021
Advaxis, Inc. today announced the initiation of its Phase 1 clinical study evaluating ADXS-504 in patients with biochemically recurrent prostate cancer.
-
IDEAYA Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
7/12/2021
IDEAYA Biosciences, Inc. (Nasdaq:IDYA) today announced the closing of its underwritten public offering of 5,333,333 shares of its common stock at a public offering price of $17.25 per share, before underwriting discounts and commissions, including the exercise in full by the underwriters of their option to purchase up to an additional 695,652 shares of common stock in the offering
-
IDEAYA Announces Pricing of Public Offering of Common Stock - July 08, 2021
7/8/2021
IDEAYA Biosciences, Inc. announced the pricing of an underwritten public offering of 4,637,681 shares of its common stock at a public offering price of $17.25 per share, before underwriting discounts and commissions.
-
IDEAYA Announces Proposed Public Offering of Common Stock - July 06, 2021
7/6/2021
IDEAYA Biosciences, Inc. announced that it intends to offer and sell up to $80 million of shares of its common stock in an underwritten public offering.
-
SOPHiA DDM(TM) for TSO500 Furthers Analytical Capabilities
7/1/2021
SOPHiA GENETICS, the creator of a global data-sharing network that advances data-driven medicine, is adding a new Comprehensive Genomic Profiling workflow to its DDM platform.
-
Foundation Medicine Collaborates on Research Published in The New England Journal of Medicine That Identifies Resistance to KRAS Inhibitors and Underscores Need for Novel Therapeutic Strategies
6/24/2021
Foundation Medicine, Inc. and its collaborators announced results from a Dana-Farber Cancer Institute-led study that used genomic testing, including Foundation Medicine’s liquid-based comprehensive genomic profiling test, FoundationOne®Liquid CDx, among several assays, to investigate resistance mechanisms in 38 patients with cancer treated with a KRAS G12C inhibitor.
-
DeepVerge plc: Microtox® PD claims world first live data alerts of SARS-Cov-2 in wastewater treatment plants
6/24/2021
DeepVerge, announces the successful completion of Phase 3 field trials in which Microtox® PD achieved real-time detection and transmission of data, specific to SARS-CoV-2, in wastewater treatment plants at multiple sites.
-
Akoya Announces Publication of New Immunotherapy Biomarker Signature in Science, Leveraging Principles of Astronomy and Pathology
6/10/2021
Akoya Biosciences Inc., announced today that its Phenoptics solution contributed to the successful development of a novel platform, titled AstroPath.
-
Hemoglobin Feed Market: Increase in Demand from Aquaculture Sector to Bolster Market Growth
6/7/2021
According to the report, the global hemoglobin feed market was valued at US$ 216.9 Mn in 2019 and is projected to expand at a CAGR of 4% from 2020 to 2030.
-
Circular Dichroism (CD) Spectrometers Market: North America to Dominate Globally Due to High Investments by Research Firms in Market
5/25/2021
The global circular dichroism spectrometer market is anticipated to grow due to presence of several regional and international players.
-
Microdermabrasion Devices Market: Increase in prevalence of skin-related issues to drive the market
5/21/2021
The global microdermabrasion devices market was valued at around US$ 150 Mn in 2017.
-
Microdermabrasion Devices Market: Increase in prevalence of skin-related issues to drive the market
5/21/2021
The global microdermabrasion devices market was valued at around US$ 150 Mn in 2017.
-
Transcenta Announced the Results of the Phase I Clinical Study of PD-L1 Antibody MSB2311 with Advanced Solid Tumors and Hematological Malignancies
5/20/2021
Transcenta Holding Limited ("Transcenta"), a global biotherapeutics company with fully-integrated capabilities in discovery, development and manufacturing of antibody-based therapeutics, announced that the updated Phase I clinical study (NCT04272944) data on the safety and efficacy of MSB2311, a pH-dependent PD-L1 antibody
-
H3 Biomedicine Announces Presentation of Four Abstracts at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting
5/20/2021
H3 Biomedicine Inc. (H3), a U.S.-based precision medicine research & development subsidiary of Eisai Co., Ltd., today announced the presentation of four posters providing updated investigational data on its H3B-6545 clinical program for breast cancer and its H3B-6527 clinical program for hepatocellular carcinoma at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, being held virtually June 4–8,
-
Ziopharm Oncology Reinforces Clear and Bold Vision for Delivering Value at Annual Shareholders Meeting
5/19/2021
Ziopharm Oncology, Inc., held its annual shareholders meeting and reinforced its plan and vision for the Company developed and endorsed by the Board and management team.
-
Advaxis Presents Updated Clinical Data from Ongoing Phase 1/2 Trial of ADXS-503 in NSCLC at the American Society of Clinical Oncology (ASCO) 2021 Annual Meeting
5/19/2021
Updated data show disease control rate of 44% with durable clinical benefit observed beyond one year in patients with disease progression on pembrolizumab
-
Sterile Vials Market Sales Set to Grow at 8.5% Backed by Surging Demand for Glass Sterile Vials: Fact.MR
5/17/2021
Rising demand from clinical and compounding labs for sterile vials will provide growth opportunities to manufacturers over the coming years